Potential predictors of acne relapse after systemic isotretinoin therapy: a literature review
https://doi.org/10.33667/2078-5631-2025-23-47-51
Abstract
Acne relapse following completion of systemic isotretinoin therapy remains a significant clinical problem, with recurrence rates ranging from 9% to 65%. This review analyzes existing data on potential predictors of acne relapse and the role of cumulative dose and various daily dosing regimens of systemic isotretinoin in maintaining long‑term remission. We emphasize that the lack of comparability in results across different studies is largely due to methodological differences (heterogeneous patient populations, the absence of a standardized definition for «acne relapse»). The article underscores the urgent need to unify relapse criteria for a comprehensive assessment of prognostic factors to create personalized treatment approaches for acne patients, taking into account the individual relapse risks and optimizing systemic isotretinoin dosing regimens.
About the Authors
E. E. Konstantinovskaya
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
Konstantinovskaya Ekaterina E., applicant at Dept of Dermatovenereology and Cosmetology
Moscow
K. B. Olkhovskaya
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
Olkhovskaya Kira B., PhD Med, associate professor at Dept of Dermatovenereology and Cosmetology
Moscow
A. N. Protsenko
N.I. Pirogov Russian National Research Medical University (Pirogov University)
Russian Federation
Russian Federation
Protsenko Alexey N., PhD Med, associate professor at Dept of Dermatovenereology named after Academician Yu.K. Skripkin of the Institute of Clinical Medicine
Moscow
References
1. Tuchayi S.M., Makrantonaki E., Ganceviciene R., et al. Acne vulgaris. Nat Rev Dis Primers. 2015; 1 (1): 15029. DOI:10.1038/nrdp.2015.29
2. Vos T., Flaxman A.D., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012; 380 (9859): 2163–2196. DOI: 10.1016/s0140–6736(12)61729
3. Heng A.H.S., Chew F.T. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020; 10 (1): 5754. DOI: 10.1038/s41598-020-62715-3
4. Woodie B.R., Holt I.N., Freking J.A., et al. Severity of acne vulgaris predicts maladaptive psychosocial perceptions and neuropsychiatric disorders: a case control study. Arch Dermatol Res. 2025; 317 (1): 597. DOI: 10.1007/s00403–025–04123-z
5. Reynolds R.V., Yeung H., Cheng C.E., et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2024; 90 (5): 1006. e1–1006.e30. DOI: 10.1016/j.jaad.2023.12.017
6. Landis M.N. Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol. 2020; 21 (3): 411–419. DOI: 10.1007/s40257-020-00508-0
7. Kruglova L.S., Gryazeva N.V., Tamrazova A.V. Systemic treatment of moderate acne: pathogenetically substantiated choice of therapy. Medical alphabet. 2022; 8: 29 33. (In Russ.). DOI: 10.33667/2078-5631-2022-8-29-33
8. Thiboutot D.M., Dréno B., Abanmi A., et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology. 2018; 78 (2): S1 S23.e1. DOI: 10.1016/j.jaad.2017.09.078
9. Al Mutairi N., Manchanda Y., Nour Eldin O., Sultan A. Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait. J Drugs Dermatol. 2005; 4 (3): 369–373.
10. Quéreux G., Volteau C., N’Guyen J.M., Dréno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology. 2006; 212 (2): 168–176. DOI: 10.1159/000090658
11. Lehucher Ceyrac D., De La Salmonière P., Chastang C., Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology. 1999; 198 (3): 278–283. DOI: 10.1159/000018130
12. White G.M., Chen W., Yao J., Wolde Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998; 134 (3): 376–378. DOI: 10.1001/archderm.134.3.376
13. Demirci Saadet E. Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris. Dermatologic Therapy. 2021; 34 (6): e15109. DOI: 10.1111/dth.15109
14. Lai J., Barbieri J.S. Acne relapse and isotretinoin retrial in patients with acne. JAMA Dermatol. 2025; 161 (4): 367. DOI: 10.1001/jamadermatol.2024.5416
15. Morales Cardona C.A., Sánchez Vanegas G. Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. Actas Dermosifiliogr. 2013; 104 (1): 61–66. DOI: 10.1016/j.ad.2012.05.004
16. Perlamutrov Yu.N., Olkhovskaya K.B., Soloviev A.M., Lyapon A.O. Determination of key prognostic factors for the development of acne recurrence after therapy with systemic isotretinoin. Consilium Medicum. 2022; 24 (8): 529–533. (In Russ.). DOI: 10.26442/20751753.2022.8.201753
17. Azoulay L., Oraichi D., Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case control study. Br J Dermatol. 2007; 157 (6): 1240–1248. DOI: 10.1111/j.1365–2133.2007.08250.x
18. Liu A., Yang D. J., Gerhardstein P. C., Hsu S. Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients. J Drugs Dermatol. 2008; 7 (10): 963–966.
19. Borghi A., Mantovani L., Minghetti S., et al. Low cumulative dose isotretinoin treatment in mild to moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol. 2011; 25 (9): 1094–1098. DOI: 10.1111/j.1468–3083.2010.03933.x
20. Coloe J., Du H., Morrell D.S. Could higher doses of isotretinoin reduce the frequency of treatment failure in patients with acne? J Am Acad Dermatol. 2011; 65 (2): 422–423. DOI: 10.1016/j.jaad.2010.06.025
21. Blasiak R.C., Stamey C.R., Burkhart C.N., et al. High dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013; 149 (12): 1392. DOI: 10.1001/jamadermatol.2013.6746
22. Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Aust J Dermatology. 2010; 51 (4): 248–253. DOI: 10.1111/j.1440–0960.2010.00657.x
23. Nascimento C.R., Martins A.L.G.P., Milagres S.P., Bastazini Jr I. Acne recurrence after treatment with oral isotretinoin: 5 year follow up. Surg Cosmet Dermatol. 2011; 3 (3): 188–191.
24. Haryati I., Jacinto S.S. Profile of acne patients in the Philippines requiring a second course of oral isotretinoin. Int J Dermatol. 2005; 44 (12): 999 1001. DOI: 10.1111/j.1365–4632.2005.02284.x
25. Lee J.W., Yoo K.H., Park K.Y., et al. Effectiveness of conventional, low dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol. 2011; 164 (6): 1369–1375. DOI: 10.1111/j.1365–2133.2010.10152.x
26. Rademaker M. Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. Int J Dermatol. 2016; 55 (5): 518–523. DOI: 10.1111/ijd.12942
27. Sadeghzadeh Bazargan A., Ghassemi M., Goodarzi A., et al. Systematic review of low dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies. Dermatol Ther. 2021; 34 (1): e14438. DOI: 10.1111/dth.14438
28. Al Muqarrab F., Almohssen A. Low dose oral isotretinoin for the treatment of adult patients with mild to moderate acne vulgaris: Systematic review and meta analysis. Dermatologic Therapy. 2022; 35 (4): e15311. DOI: 10.1111/dth.15311
29. Kassem B., Ismail M., Hassan F. Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study. Dermatologic Therapy. 2022; 35 (12): e15974. DOI: 10.1111/dth.15974
30. Goulden V., Clark S.M., McGeown C., Cunliffe W.J. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997; 137 (1): 106–108.
31. Cakir G.A., Erdogan F.G., Gurler A. Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse. Int J Dermatol. 2013; 52 (3): 371–376. DOI: 10.1111/j.1365–4632.2012.05691.x
32. Bettoli V., Borghi A., Zauli S., et al. Maintenance therapy for acne vulgaris: efficacy of a 12 month treatment with adapalene benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology. 2013; 227 (2): 97–102. DOI: 10.1159/000350820
33. Truchuelo M.T., Jiménez N., Mavura D., Jaén P. Assessment of the efficacy and safety of a combination of 2 topical retinoids (RetinSphere) in maintaining post treatment response of acne to oral isotretinoin. Actas Dermosifiliogr. 2015; 106 (2): 126–132. DOI: 10.1016/j.ad.2014.09.001
Review
For citations:
Konstantinovskaya E.E., Olkhovskaya K.B., Protsenko A.N. Potential predictors of acne relapse after systemic isotretinoin therapy: a literature review. Medical alphabet. 2025;1(23):47-51. (In Russ.) https://doi.org/10.33667/2078-5631-2025-23-47-51
Views:
12
Email this article 